Company news

Protara Therapeutics, Inc. news in 2024

Protara Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Protara Announces Closing of $100 Million Public Offering

December 10, 2024

Protara Announces Pricing of $100 Million Public Offering

December 8, 2024

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

December 4, 2024

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

December 2, 2024

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

November 14, 2024

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

November 11, 2024

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

November 5, 2024

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

October 20, 2024

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

September 8, 2024

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

September 8, 2024

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

August 5, 2024

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2024

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 20, 2024

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

April 4, 2024

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

April 4, 2024

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

April 4, 2024

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 12, 2024

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

February 27, 2024

Decks in 2024